Compare State Street SPDR S&P Biotech ETF (XBI) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR S&P Biotech ETF vs Consumer Staples Select Sector SPDR Fund — how do they compare? State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B), while Consumer Staples Select Sector SPDR Fund trades at $83.43 (market cap $13.50B). The key difference: Consumer Staples Select Sector SPDR Fund is the larger of the two by market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Consumer Staples Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR S&P Biotech ETF for 38 Days and Consumer Staples Select Sector SPDR Fund for 72 Days on average.
| XBI | XLP | |
|---|---|---|
Market Cap | $10.11B | $13.50B |
Volume | 12,903,266 | 14,599,953 |
Sector | Broad Market / Factor | — |
52-Week High | $169.55 | $90.00 |
52-Week Low | $104.99 | $75.61 |
Typical Hold Time | 38 Days | 72 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
XLP (Consumer Staples Select Sector SPDR ETF) trades at $83.42, up 2.11% with a bullish technical signal supported by moving averages and oscillators. The ETF shows strong defensive characteristics amid market volatility, with 100% analyst buy ratings and a forthcoming dividend. Recent news highlights its outperformance versus discretionary sectors and competitive positioning against peers like VDC and IYK.
Outlook remains positive given defensive sector strength and favorable expense ratio, though risks include interest rate sensitivity and consumer spending shifts. The ETF's focus on household staples provides stability, but elevated RSI levels suggest near-term consolidation potential before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
